European Society of Cardiology (ESC) Congress 2026
Munich, Germany & Online 28 August 2026 - 31 August 2026
AI + mammography: A new gateway for CVD detection?
A retrospective analysis presented at ESC 2026 demonstrates the ability of artificial intelligence (AI) to detect cardiovascular diseases (CVDs) from routine mammograms.
AI + mammography: A new gateway for CVD detection?
15 Sep 2026
Aficamten retains upper hand over metoprolol for oHCM in subanalysis
Results from a subanalysis of the MAPLE-HCM* trial presented at ESC 2026 continue to support the superiority of aficamten over metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) irrespective of beta-blocker (BB) use at screening and prior standard-of-care (SoC) status.
Aficamten retains upper hand over metoprolol for oHCM in subanalysis
14 Sep 2026
Inclisiran outdoes BPA for LDL-C lowering in high CV risk patients
In the phase IV VICTORION-Challenge trial, inclisiran outperforms bempedoic acid (BPA) for lowering LDL-C in individuals with high and very high cardiovascular (CV) risk.
Inclisiran outdoes BPA for LDL-C lowering in high CV risk patients
11 Sep 2026
SHASTA trials boost plozasiran potential in severe hypertriglyceridaemia
In the SHASTA-3 and SHASTA-4 trials, quarterly administration of plozasiran reduced triglyceride (TG) levels and acute pancreatitis (AP) events in individuals with severe hypertriglyceridaemia (sHTG; TG ≥500 mg/dL).
SHASTA trials boost plozasiran potential in severe hypertriglyceridaemia
10 Sep 2026
Tailored therapy reduces antibiotic use in infective endocarditis
A response-tailored strategy decreases antibiotic duration by 2 weeks compared with standard therapy in patients with left-sided infective endocarditis, without compromising their safety. This is the primary result of the POET-II study presented at ESC Congress 2026.